Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

5(83.3%)

Phase 2

1(16.7%)

6Total

Phase 1(5)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05190471Phase 1Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Role: lead

NCT02781883Phase 2Recruiting

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Role: lead

NCT04196257Phase 1Recruiting

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Role: lead

NCT04072458Phase 1Active Not Recruiting

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Role: lead

NCT02923986Phase 1Withdrawn

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Role: lead

NCT01159028Phase 1Completed

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

Role: lead

All 6 trials loaded